Comparison of Intra-Arterial Chemotherapy Efficacy Delivered Through the Ophthalmic Artery or External Carotid Artery in a Cohort of Retinoblastoma Patients.
Comparison of Intra-Arterial Chemotherapy Efficacy Delivered Through the Ophthalmic Artery or External Carotid Artery in a Cohort of Retinoblastoma Patients.
复制标题
在一组视网膜母细胞瘤患者中通过眼动脉或颈外动脉进行动脉内化疗的疗效比较。
DOI：
10.3389/fmed.2021.658305
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
Fan X
中科院分区：
文献类型：
--
作者：
Jia S;Wen X;Zhou M;He X;Han M;Fan J;Jia R;Fan X
目的：评价颈外动脉（ECA）替代动脉化疗（IAC）治疗视网膜母细胞瘤的疗效。方法：在这项回顾性、单中心、病例对照研究中，纳入了98例成功接受IAC治疗的视网膜母细胞瘤患者。给药途径为眼初级动脉（OA）途径，当OA置管不可行时，通过ECA途径给药。结果：本研究共进行了337例成功的IAC手术，其中32例（9.5%）通过ECA途径进行。18只眼（18.4%）通过ECA分支机构接受了至少一次IAC。统计分析显示，ECA和OA两种途径的眼部临床结果（去核、死亡、复发和无事件）无显著差异。给药途径与眼部生存时间无显著相关性（p = 0.69）。在至少一个IAC周期内使用ECA导管并不是去核的预测因子（HR: 1.58; 95% CI: 0.56-4.46, p = 0.39）。通过ECA途径的手术次数增加并没有增加去核的风险（HR: 1.64; 95% CI: 0.42-6.39, p = 0.48）。结论：ECA替代途径不影响IAC治疗视网膜母细胞瘤的疗效。当标准OA入路不可行时，应考虑ECA系统置管。
Purpose: To evaluate the efficacy of an external carotid artery (ECA) alternative route in intra-arterial chemotherapy (IAC) for treatment of retinoblastoma. Methods: In this retrospective, single-centre, case-control study, 98 retinoblastoma patients who received successful IAC were included. The drug delivery routes were the primary ophthalmic artery (OA) route and the ECA route when OA catheterization was not feasible. Results: A total of 337 successful IAC procedures were performed in our study, of which 32 (9.5%) procedures were performed through the ECA route. Eighteen eyes (18.4%) accepted at least one IAC through branches of the ECA. Statistical analysis showed that there was no significant difference in ocular clinical results (enucleation, death, recurrence and event-free) between the ECA and OA routes. No significant association was found between the route of drug delivery and the ocular survival time (p = 0.69). The use of ECA catheterization in at least one IAC cycle was not a predictor of enucleation (HR: 1.58; 95% CI: 0.56–4.46, p = 0.39). The increasing number of procedures through the ECA route did not increase the risk of enucleation (HR: 1.64; 95% CI: 0.42–6.39, p = 0.48). Conclusion: The ECA alternative route did not affect the efficacy of IAC in retinoblastoma. When the standard OA approach is not feasible, ECA system catheterization should be considered.